Effect of Shenkang granules on the progression of chronic renal failure in 5/6 nephrectomized rats

Zhang,Yu; Zhou,Nan; Wang,Hongying; Wang,Sicen; He,Jianyu

doi:10.3892/etm.2015.2383

Effect of Shenkang granules on the progression of chronic renal failure in 5/6 nephrectomized rats

Authors:
- Yu Zhang
- Nan Zhou
- Hongying Wang
- Sicen Wang
- Jianyu He
View Affiliations

Affiliations: School of Medicine, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: March 24, 2015 https://doi.org/10.3892/etm.2015.2383
Pages: 2034-2042
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Shenkang granules (SKGs) are a Chinese herbal medicinal formula, consisting of rhubarb (Rheum palmatum L.), Salvia miltiorrhiza, milkvetch root [Astragalus membranaceus (Fisch.) Bunge] and safflower (Carthamus tinctorius L.). The aim of the present study was to investigate the effect of SKG on chronic renal failure (CRF) in 5/6 nephrectomized (5/6 Nx) rats. The rats were randomly divided into seven groups (n=10 per group) as follows: (i) 5/6 Nx (model group; 2.25 ml/kg/day normal saline); (ii) SKGL (low dose; 5/6 Nx treated with 2 g crude drug/kg/day SKG); (iii) SKGM (moderate dose; 5/6 Nx treated with 4 g crude drug/kg/day SKG); (iv) SKGH (high dose; 5/6 Nx treated with 8 g crude drug/kg/day SKG); (v) benazepril treatment group (5/6 Nx treated with 5 mg/kg/day benazepril); (vi) Shenkang injection (SKI) group (5/6 Nx with 13.3 ml/kg/day SKI); and (vii) sham‑operated group (2.25 ml/kg/day normal saline). After 30 days, the levels of microalbumin, total protein, serum creatinine, blood urea nitrogen and serum lipid were found to be significantly decreased in the SKGL and SKGM rats, showing histological improvement compared with the untreated 5/6 Nx rats, as determined by hematoxylin and eosin, and Masson's trichrome staining. In addition, SKG was found to significantly improve the levels of glutathione peroxidase and reduce the damage caused by free radicals to the kidney tissues. Furthermore, SKG prevented the accumulation of extracellular matrix by decreasing the expression of collagen I and III and inhibiting the expression of matrix metalloproteinases‑2 and ‑9 in the renal tissue, as determined by western blot analysis. SKG was also shown to decrease the concentrations of serum transforming growth factor‑β1, as determined by ELISA, and kidney angiotensin II, as determined using a radioimmunoassay kit. In conclusion, SKG was demonstrated to ameliorate renal injury in a 5/6 Nx rat model of CRF. Thus, SKG may exert a good therapeutic effect on CRF.

View Figures

View References

1	Norman JT and Fine LG: Progressive renal disease: fibroblasts, extracellular matrix, and integrins. Exp Nephrol. 7:167–177. 1999. View Article : Google Scholar : PubMed/NCBI
2	Rossert J, Fouqueray B and Boffa JJ: Anemia management and the delay of chronic renal failure progression. J Am Soc Nephrol. 14:(7 Suppl 2). S173–S177. 2003. View Article : Google Scholar : PubMed/NCBI
3	Sasaki S, Tohda C, Kim M and Yokozawa T: Gamma-aminobutyric acid specifically inhibits progression of tubular fibrosis and atrophy in nephrectomized rats. Biol Pharm Bull. 30:687–691. 2007. View Article : Google Scholar : PubMed/NCBI
4	Tsujimura T, Nagamine J, Sugaru E, et al: Combination therapy with SMP-534 and an angiotensin-converting enzyme inhibitor provides additional renoprotection in 5/6 nephrectomized rats. Biol Pharm Bull. 32:1991–1996. 2009. View Article : Google Scholar : PubMed/NCBI
5	El Nahas Meguid A and Bello AK: Chronic kidney disease: the global challenge. Lancet. 365:331–340. 2005. View Article : Google Scholar : PubMed/NCBI
6	Dellê H, Rocha JR, Cavaglieri RC, Vieira JM Jr, Malheiros DM and Noronha IL: Antifibrotic effect of tamoxifen in a model of progressive renal disease. J Am Soc Nephrol. 23:37–48. 2012. View Article : Google Scholar : PubMed/NCBI
7	Jian DY, Chao YW, Ting CH, et al: Losartan ameliorates renal injury, hypertension, and adipocytokine imbalance in 5/6 nephrectomized rats. Eur J Pharmacol. 709:85–92. 2013. View Article : Google Scholar : PubMed/NCBI
8	Cho KH, Kim HJ, Kamanna VS and Vaziri ND: Niacin improves renal lipid metabolism and slows progression in chronic kidney disease. Biochim Biophys Acta. 1800:6–15. 2010. View Article : Google Scholar : PubMed/NCBI
9	Iyoda M, Shibata T, Wada Y, et al: Long- and short-term treatment with imatinib attenuates the development of chronic kidney disease in experimental anti-glomerular basement membrane nephritis. Nephrol Dial Transplant. 28:576–584. 2013. View Article : Google Scholar : PubMed/NCBI
10	Wang C, Duan H and He L: Inhibitory effect of atractylenolide I on angiogenesis in chronic inflammation in vivo and in vitro. Eur J Pharmacol. 612:143–152. 2009. View Article : Google Scholar : PubMed/NCBI
11	Du J, Chen H and Wang XB: Effect of shenkang injection on hypertrophy and expressions of p21 and p27 in glomerular mesangial cells of rats cultured in high glucose. Zhongguo Zhong Xi Yi Jie He Za Zhi. 26:(Suppl). 68–71. 2006.[(In Chinese)]. PubMed/NCBI
12	Xiao W, Wei LB, Ma Y, Long HB and Chen GB: Renal protective effect of Shenkang pill on diabetic rats. Zhongguo Zhong Yao Za Zhi. 31:1006–1009. 2006.[(In Chinese)]. PubMed/NCBI
13	Guo L, Liu Y and Mao W: Contrast study on effect of shenkang injection and benazepril on human glomerular mesangial extracellular matrix. Zhongguo Zhong Xi Yi Jie He Za Zhi. 20:50–52. 2000.[(In Chinese)]. PubMed/NCBI
14	Zhao Z, Li H and Zhang X: Effect of shenkang injection on transforming growth factor-beta messenger ribonucleic acid of LLC-PK1 renal tubular epithelial cells. Zhongguo Zhong Xi Yi Jie He Za Zhi. 20:931–933. 2000.[(In Chinese)]. PubMed/NCBI
15	Anderson S, Rennke HG and Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest. 77:1993–2000. 1986. View Article : Google Scholar : PubMed/NCBI
16	Maschio G, Alberti D, Janin G, et al: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 334:939–945. 1996. View Article : Google Scholar : PubMed/NCBI
17	Ghosh SS, Massey HD, Krieg R, et al: Curcumin ameliorates renal failure in 5/6 nephrectomized rats: role of inflammation. Am J Physiol Renal Physiol. 296:F1146–F1157. 2009. View Article : Google Scholar : PubMed/NCBI
18	Cao L, Xu CB, Zhang Y, Cao YX and Edvinsson L: Secondhand smoke exposure induces Raf/ERK/MAPK-mediated upregulation of cerebrovascular endothelin ETA receptors. BMC Neurosci. 12:1092011. View Article : Google Scholar : PubMed/NCBI
19	Cao L, Zhang Y, Cao YX, Edvinsson L and Xu CB: Cigarette smoke upregulates rat coronary artery endothelin receptors in vivo. PLoS One. 7:e330082012. View Article : Google Scholar : PubMed/NCBI
20	Baraka A and El Ghotny S: Cardioprotective effect of renalase in 5/6 nephrectomized rats. J Cardiovasc Pharmacol Ther. 17:412–416. 2012. View Article : Google Scholar : PubMed/NCBI
21	Bai F, Makino T, Ono T and Mizukami H: Anti-hypertensive effects of shichimotsukokato in 5/6 nephrectomized Wistar rats mediated by the DDAH-ADMA-NO pathway. J Nat Med. 66:583–590. 2012. View Article : Google Scholar : PubMed/NCBI
22	Ma RX, Zhao N and Zhang W: The effects and mechanism of Tripterygium wilfordii Hook F combination with irbesartan on urinary podocyte excretion in diabetic nephropathy patients. Zhonghua Nei Ke Za Zhi. 52:469–473. 2013.[(In Chinese)]. PubMed/NCBI
23	Cozzolino M, Staniforth ME, Liapis H, et al: Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int. 64:1653–1661. 2003. View Article : Google Scholar : PubMed/NCBI
24	Tapia E, Zatarain-Barrón ZL, Hernández-Pando R, et al: Curcumin reverses glomerular hemodynamic alterations and oxidant stress in 5/6 nephrectomized rats. Phytomedicine. 20:359–366. 2013. View Article : Google Scholar : PubMed/NCBI
25	Zhao G, Zhao H, Tu L, et al: Effects and mechanism of irbesartan on tubulointerstitial fibrosis in 5/6 nephrectomized rats. J Huazhong Univ Sci Technolog Med Sci. 30:48–54. 2010. View Article : Google Scholar : PubMed/NCBI
26	Monostori P, Kocsis GF, Ökrös Z, et al: Different administration schedules of darbepoetin alfa affect oxidized and reduced glutathione levels to a similar extent in 5/6 nephrectomized rats. Clin Exp Nephrol. 17:569–574. 2013. View Article : Google Scholar : PubMed/NCBI
27	Konda T, Enomoto A, Takahara A and Yamamoto H: Effects of L/N-type calcium channel antagonist, cilnidipine on progressive renal injuries in Dahl salt-sensitive rats. Biol Pharm Bull. 29:933–937. 2006. View Article : Google Scholar : PubMed/NCBI
28	Noda M, Matsuo T, Fukuda R, et al: Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure. Kidney Int. 56:898–909. 1999. View Article : Google Scholar : PubMed/NCBI
29	Romero F, Rodríguez-Iturbe B, Parra G, González L, Herrera-Acosta J and Tapia E: Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int. 55:945–955. 1999. View Article : Google Scholar : PubMed/NCBI
30	Mori Y and Hirano T: Ezetimibe alone or in combination with pitavastatin prevents kidney dysfunction in 5/6 nephrectomized rats fed high-cholesterol. Metabolism. 61:379–388. 2012. View Article : Google Scholar : PubMed/NCBI
31	Zager RA, Johnson AC and Becker K: Acute unilateral ischemic renal injury induces progressive renal inflammation, lipid accumulation, histone modification, and ‘end-stage’ kidney disease. Am J Physiol Renal Physiol. 301:F1334–F1345. 2011. View Article : Google Scholar : PubMed/NCBI
32	Houlihan CA, Akdeniz A, Tsalamandris C, Cooper ME, Jerums G and Gilbert RE: Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care. 25:1072–1077. 2002. View Article : Google Scholar : PubMed/NCBI
33	Gaedeke J, Peters H, Noble NA and Border WA: Angiotensin II, TGF-beta and renal fibrosis. Contrib Nephrol. 135:153–160. 2001. View Article : Google Scholar : PubMed/NCBI
34	Noronha IL, Fujihara CK and Zatz R: The inflammatory component in progressive renal disease - are interventions possible? Nephrol Dial Transplant. 17:363–368. 2002. View Article : Google Scholar : PubMed/NCBI
35	He L, Shen P, Fu Q, et al: Nephro-protective effect of Kangqianling decoction on chronic renal failure rats. J Ethnopharmacol. 122:367–373. 2009. View Article : Google Scholar : PubMed/NCBI
36	Kim SK, Jung KH and Lee BC: Protective effect of Tanshinone IIA on the early stage of experimental diabetic nephropathy. Biol Pharm Bull. 32:220–224. 2009. View Article : Google Scholar : PubMed/NCBI
37	Demosthenous P, Voskarides K, Stylianou K, et al: Hellenic Nephrogenetics Research Consortium: X-linked Alport syndrome in Hellenic families: phenotypic heterogeneity and mutations near interruptions of the collagen domain in COL4A5. Clin Genet. 81:240–248. 2012. View Article : Google Scholar : PubMed/NCBI
38	Soylemezoglu O, Wild G, Dalley AJ, et al: Urinary and serum type III collagen: markers of renal fibrosis. Nephrol Dial Transplant. 12:1883–1889. 1997. View Article : Google Scholar : PubMed/NCBI
39	Ding J, Yang J, Liu J and Yu L: Immunofluorescence study of type IV collagen alpha chains in epidermal basement membrane: application in diagnosis of X-linked Alport syndrome. Chin Med J (Engl). 110:584–586. 1997.PubMed/NCBI
40	Duong Van Huyen JP, Viltard M, Nehiri T, et al: Expression of matrix metalloproteinases MMP-2 and MMP-9 is altered during nephrogenesis in fetuses from diabetic rats. Lab Invest. 87:680–689. 2007. View Article : Google Scholar : PubMed/NCBI
41	Marson BP, Lacchini R, Belo V, et al: Matrix metalloproteinase (MMP)-2 genetic variants modify the circulating MMP-2 levels in end-stage kidney disease. Am J Nephrol. 35:209–215. 2012. View Article : Google Scholar : PubMed/NCBI
42	Lee ES, Shen Q, Pitts RL, et al: Serum metalloproteinases MMP-2, MMP-9, and metalloproteinase tissue inhibitors in patients are associated with arteriovenous fistula maturation. J Vasc Surg. 54:454–460. 2011. View Article : Google Scholar : PubMed/NCBI
43	Pawlak K, Mysliwiec M and Pawlak D: Peripheral blood level alterations of MMP-2 and MMP-9 in patients with chronic kidney disease on conservative treatment and on hemodialysis. Clin Biochem. 44:838–843. 2011. View Article : Google Scholar : PubMed/NCBI